Skip to content

Released Nov 12, 2024, after the close

10-Q filed Nov 12, 2024, 43 days after period end · 0001628280-24-047130

Q3 2024 · 10-Q
Revenue$209.00K— vs Q3 2023no prior Q2 2024 on file
Net Income-$52.52MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.44N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$54,232,000N/M
Operating Cash Flowderived-$25,912,000N/M
Free Cash Flowderived-$27,189,000N/M
Margins · derived
Operating margin-25948.3%
Net margin-25128.2%

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Revenue$209.00K$0.00——
Net Income-$52.52M-$50.71M-$29.35M-$16.41M
EPS Diluted-$0.44-$0.55-$1.61-$1.52

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR